Terns Pharmaceuticals (NYSE: TERN) — Perfil da empresa, notícias e dados financeiros
Terns Pharmaceuticals develops therapies for liver disease and cancer, focusing on patient-centered innovative treatments.
Terns Pharmaceuticals
Terns Pharmaceuticals (NASDAQ:TERN) focuses on discovering, developing, and commercializing innovative therapies for significant unmet needs in the treatment of liver disease and cancer. With a deep commitment to addressing the challenges faced by patients with these life-threatening conditions, Terns operates with a vision to bring transformative treatments to the forefront. Their projects span across various stages of clinical development, leveraging both cutting-edge science and strategic partnerships to accelerate the development of their pipeline. The overarching objective of Terns is to improve patient outcomes through therapeutic advancements, embodying a patient-centric approach in everything from research to the eventual delivery of treatments. As it stands, Terns Pharmaceuticals is solely traded on the NASDAQ under the ticker symbol TERN, where it seeks to make a marked impact in the biopharmaceutical sphere by focusing on areas of high unmet medical need.
Resumo
Operações
Produtos e/ou serviços de Terns Pharmaceuticals
- Development of TERN-101, a liver-distributed farnesoid X receptor agonist designed for the treatment of NASH (non-alcoholic steatohepatitis).
- Working on TERN-201, a semicarbazide-sensitive amine oxidase inhibitor for potential vascular adhesion protein-1 blockade, aimed at addressing NASH.
- Advancement of TERN-501, a thyroid hormone receptor beta agonist, targeting the treatment of NASH.
- Research on TERN-601, a small molecule diacylglycerol O-acyltransferase 2 inhibitor, aiming to treat NASH.
- Exploring TERN-301 as a novel treatment option for NASH, details on its mechanism and specific target remain under research.
- Provision of a comprehensive pipeline focused on developing therapeutic candidates for NASH and other chronic liver diseases.
equipe executiva do Terns Pharmaceuticals
- Ms. Amy L. Burroughs M.B.A.CEO & Director
- Ms. Melita Sun JungChief Business Officer
- Mr. Andrew W. GengosCFO & Head of Corporate Development
- Ms. Caryn Gordon McDowell J.D.Chief Legal Officer
- Ms. Robin AndrulevichChief People Officer
- Dr. Jeffrey R. Jasper Ph.D.Senior Vice President of Research
- Dr. Emil T. Kuriakose M.D.Chief Medical Officer
- Mr. Scott HarrisChief Development Officer
- Ms. Debra SieminskiSenior Vice President of Medical Affairs
- Mr. James KanterSenior VP of CMC
Principais indicadores financeiros
Resultados divulgados pela Terns Pharmaceuticals, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -110,1 mi | -96,2 mi | |
| 0 | -101,9 mi | -88,9 mi | |
| 0 | -102,6 mi | -90,2 mi | |
| 0 | -62 mi | -60,3 mi |